

February 26, 2014

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (BC-65) ANDEXANET ALFA
 PRONUNCIATION an dex' a net al' fa
 THERAPEUTIC CLAIM Reversal of anticoagulation caused by Factor Xa inhibitors
 CHEMICAL NAMES

1. Blood-coagulation factor Xa (human mutant)
2. Recombinant inactivated Factor Xa containing Gla-domain deletion and S290A mutation

STRUCTURAL FORMULA

Sequence

ANSFLFWNKY	KDGDQCETSP	CQNQGKCKDG	LGEYTCTCLE	GFEGKNCELF	50
TRKLCSLDNG	DCDQFCHEEQ	NSVVCSCARG	YTLADNGKAC	IPTGPYPCKG	100
QTLERIVGGQ	ECKDGECPWQ	ALLINEENEG	FCGGTILSEF	YILTAHCLY	150
QAKRFKVRVG	DRNTEQEEGG	EAVHEVEVVI	KHNRFTKETY	DFDIAVLRLLK	200
TPITFRMNVA	PACLPERDWA	ESTLMTQKTG	IVSGFGRTHE	KGRQSTRLLK	250
LEVPYVDRNS	CKLSSSFIIT	QNMFCAGYDT	KQEDACQGDA	GGPHVTRFKD	300
TYFVTGIVSW	GEGCARKGKY	GIYTKVTAFL	KWIDRSMKTR	GLPKAKSHAP	350
EVITSSPLK					359

Disulfide bridges

Intra-L-L	C16-C27	C21-C36	C38-C47	C55-C66	
	C62-C75	C77-C90			
Intra-H-H	C112-C117	C132-C148	C261-C275	C286-C314	
Inter-H-L	C98-C213				

Glycosylation sites

T354	type: 1 HexNAc/1 Hex/2SA

MOLECULAR FORMULA C₁₇₅₀ H₂₇₂₇ N₄₈₉ O₅₃₉ S₂₇

MOLECULAR WEIGHT 40,102.4 Da (calculated from the cDNA derived protein sequence)

TRADEMARK None as yet

ANDEXANET ALFA

Page 2 of 2

SPONSOR

Portola Pharmaceuticals, Inc.

N14

19

CODE DESIGNATIONS

PRT064445; PRT-4445; rFXa Inhibitor Antidote

CAS REGISTRY NUMBER

1262449-58-0

UNII

BI009E452R

WHO NUMBER

9883

SCS